As a regulator, I can confirm that a USFDA Form 483 highlights critical data integrity *observations* post-inspection, and an import alert is a severe enforcement action banning products, often due to falsified data. In 2013, Ranbaxy admitted to systemic fraud—fabricating stability data and submitting false information to the USFDA. My work at the EMA shows such admissions are just the public surface; the real failure is a culture that allowed it, which takes years to rebuild, *no*? Watching your own cooking ensures quality; in pharma, that means constant, unannounced oversight.
#exams#study
Jump in to reply — no account needed.